Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.

about

Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.

Item

http://www.wikidata.org/entity/Q47107172

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Acute Lymphoblastic Leukemia P ...... itor Treatment: A Case Report.

@en

Acute Lymphoblastic Leukemia P ...... itor Treatment: A Case Report.

@nl

type

Item

label

Acute Lymphoblastic Leukemia P ...... itor Treatment: A Case Report.

@en

Acute Lymphoblastic Leukemia P ...... itor Treatment: A Case Report.

@nl

prefLabel

Acute Lymphoblastic Leukemia P ...... itor Treatment: A Case Report.

@en

Acute Lymphoblastic Leukemia P ...... itor Treatment: A Case Report.

@nl

P1476

Acute Lymphoblastic Leukemia P ...... itor Treatment: A Case Report.

@en

P2093

Ge Zhang

http://www.w3.org/2001/XMLSchema#string

Jianrong Wu

http://www.w3.org/2001/XMLSchema#string

Yan Chen

http://www.w3.org/2001/XMLSchema#string

Yanle Zhang

http://www.w3.org/2001/XMLSchema#string

Zhigui Ma

http://www.w3.org/2001/XMLSchema#string

P2860

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

Philadelphia-positive acute lymphoblastic leukemia: current treatment options

Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.

P304

1204-1208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12659/AJCR.906300

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29133777

http://www.w3.org/2001/XMLSchema#string

P932

5700447

http://www.w3.org/2001/XMLSchema#string